Along with drug discovery, AI can be applied across a wide range of other functions
According to GlobalData, Artificial Intelligence will transform the pharmaceutical industry by delivering productivity improvements and efficiencies across the entire pharma value chain.
The report highlights that AI is expected to be the emerging technology that will have the greatest impact on the pharmaceutical industry in 2021, as indicated by 36% of 198 surveyed pharmaceutical industry professionals.
In drug discovery, many pharmaceutical companies have partnered with AI vendors or startups to take advantage of their technology and expertise. Examples of AI vendors operating in this space include Exscientia, Atomwise, Recursion Pharma, Insilico Medicine, and BenevolentAI. Pharma companies are also beginning to set up more in-house capabilities, as seen by GSK and Novartis.
This research identified nearly 100 partnerships between AI vendors and large pharma companies for drug discovery since 2015, with increasing numbers witnessed in recent years. The analysis shows that four partnerships were forged in 2015, which rose to 27 by 2020, an increase of 575% in just six years.
We’ve reported that Israel is currently on track to be the first country in the world to inoculate its entire population.